<DOC>
	<DOCNO>NCT02886858</DOCNO>
	<brief_summary>While electroconvulsive therapy ( ECT ) major depression effective , high relapse rate cognitive side effect limit long-term use . There consensus optimal continuation pharmacological treatment ECT course . Adjunction tDCS pharmacological continuation treatment ECT may decrease relapse rate .</brief_summary>
	<brief_title>tDCS Prevention Relapse After Electroconvulsive Therapy</brief_title>
	<detailed_description>In prospective , randomize , double blind , control , long-term study , investigator assign 40 depressed patient , remission ECT course associate venlafaxine , lithium adjunction ECT course , either tDCS sham tDCS . Depressive symptom cognition assess acute ECT six month continuation therapy .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>1875 an Remission ( MADRS &lt; 10 ) major depressive episode acute treatment ECT + venlafaxine Lithium adjunction 48h last ECT session No comorbid psychiatric disorder , exclude personality disorder nicotine dependance . Capacity consent Sufficient comprehension French language Contraindications tDCS Neurologic condition Severe medical condition . Pregnancy/breastfeeding . Current use benzodiazepine antipsychotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Moods disorder</keyword>
	<keyword>electroconvulsive therapy</keyword>
</DOC>